Sage Therapeutics to provide pipeline update at JPMorgan Healthcare Conference
Sage Therapeutics announced that in a corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CEOJeff Jonas, M.D., will discuss several components of the company's strategy to build the business for the long term by assembling the capabilities to fully develop and commercialize important medicines. His remarks will highlight three key areas of focus in the pursuit of new classes of CNS therapies: impacting novel, fundamental brain mechanisms; addressing treatment gaps with differentiated therapies; and discovering a potentially groundbreaking approach to depressive disorders. Dr. Jonas will provide additional detail on the following development programs: Brexanolone: Sage is currently focused on launch readiness and building commercial infrastructure to ensure successful commercial execution, if Sage's proprietary formulation brexanolone is approved to address postpartum depression, a common biological complication of childbirth. SAGE-217 and SAGE-324: Sage's novel, oral, next-generation positive allosteric modulators of synaptic and extra-synaptic GABAA receptors. GABA Discovery Programs: Evaluating a series of novel GABAA receptor modulators in pre-clinical development, including SAGE-689, SAGE-105, and others. NMDA Programs: Sage's novel, oral, first-in-class oxysterol-based positive allosteric modulators of the NMDA receptor. The company recently selected SAGE-904 as its second NMDA receptor positive allosteric modulator product candidate for development. Positive modulation of NMDA receptors may have potential in the treatment of a range of neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. Sage ended 2017 with approximately $518M of cash, cash equivalents and marketable securities, including $325.7M in net proceeds from a public offering completed in November 2017. Based on its current operating plans, Sage expects that its operating expenses will increase year over year in 2018 to support continued pipeline advancement and potential product commercialization of brexanolone in PPD. Sage expects to provide specific 2018 financial guidance in Q4 and FY17 financial results announcement in February 2018.